CNTB
NASDAQConnect Biopharma Holdings Limited
Price$0.90+0.03 (+2.90%)
01:30 PM03:15 PM
News · 26 weeks29+133%
2026-04-192026-10-11
Mix1490d
- Other4(29%)
- SEC Filings4(29%)
- Earnings2(14%)
- Insider2(14%)
- Offering1(7%)
- Analyst1(7%)
Latest news
25 items- ANALYSTLeerink Partners resumed coverage on Connect Biopharma with a new price targetLeerink Partners resumed coverage of Connect Biopharma with a rating of Outperform and set a new price target of $4.00
- SECSEC Form SCHEDULE 13G filed by Connect Biopharma Holdings LimitedSCHEDULE 13G - Connect Biopharma Holdings Ltd (0001835268) (Subject)
- INSIDERDirector Xanthopoulos Kleanthis Gabriel was granted 5,000 units of Ordinary Shares, increasing direct ownership by 6% to 91,554 units (SEC Form 4)4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- INSIDERDirector Liu Jean I was granted 8,984 units of Ordinary Shares, increasing direct ownership by 76% to 20,763 units (SEC Form 4)4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- PR3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose YoursDENVER, Sept. 30, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is heading into a stretch of unusually dense catalysts, with regulatory meetings, Phase 2 readouts, potential Phase 3 transitions and blockbuster cardiometabolic data converging for NeOnc Technologies Holdings (NASDAQ:NTHI), Connect Biopharma (NASDAQ:CNTB), Valion Bio (NASDAQ:VBIO), and Eli Lilly and Company (NYSE:LLY). NeOnc: November FDA Meeting Puts NEO212 Under the Microscope NeOnc (NASDAQ:NTHI) is moving toward a potentially important regulatory checkpoint with an in-person End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration scheduled for November 17, 2026. The meeting concerns
- SECConnect Biopharma Holdings Limited filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- PRConnect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations through one month by 85% (p=0.030) – – Rademikibart significantly reduced the rate of hospitalizations or emergency department visits for new acute COPD exacerbations by 100% (p=0.0137) – – Rademikibart was well tolerated in COPD patients experiencing an acute exacerbation with a lower incidence of adverse events than placebo – – Connect plans to engage with the U.S. Food and Drug Administration (FDA) to gain alignment on a Phase 3 program – – Company to host a conference ca
- SECConnect Biopharma Holdings Limited filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- PRConnect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo – – Rademikibart was well tolerated in asthma patients experiencing an acute exacerbation with a low incidence of adverse events– – Data from Seabreeze STAT COPD study of rademikibart will be available later this month after which Connect plans to engage with the U.S. Food and Drug Administration (FDA) to gain alignment on a Phase 3 program – – Company to host a conference call to discuss the data today, September 15 at 8:00 a.m. ET – SAN DIEGO, Sept. 15, 2026 (GLOBE
- PRConnect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 11:30 a.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Connect Biopharma Holdings LimitedSCHEDULE 13G/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)
- SECSEC Form 10-Q filed by Connect Biopharma Holdings Limited10-Q - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- SECConnect Biopharma Holdings Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- PRConnect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and six months ended June 30, 2026, and provided a business update. "During the second quarter, w
- INSIDERDirector Xanthopoulos Kleanthis Gabriel was granted 3,738 units of Ordinary Shares, increasing direct ownership by 5% to 86,554 units (SEC Form 4)4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- INSIDERDirector Liu Jean I was granted 6,718 units of Ordinary Shares, increasing direct ownership by 133% to 11,779 units (SEC Form 4)4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- ANALYSTPiper Sandler initiated coverage on Connect Biopharma with a new price targetPiper Sandler initiated coverage of Connect Biopharma with a rating of Overweight and set a new price target of $7.00
- PRConnect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating the safety and efficacy of rademikibart, the Company's next-generation, potentially best-in-class anti-interle
- INSIDERDirector Huang James bought $371,610 worth of Ordinary Shares (150,000 units at $2.48) (SEC Form 4)4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- SECSEC Form EFFECT filed by Connect Biopharma Holdings LimitedEFFECT - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on Connect Biopharma with a new price targetCanaccord Genuity initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $6.00
- ANALYSTCantor Fitzgerald initiated coverage on Connect Biopharma with a new price targetCantor Fitzgerald initiated coverage of Connect Biopharma with a rating of Overweight and set a new price target of $4.00
- SECSEC Form F-3 filed by Connect Biopharma Holdings LimitedF-3 - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- PRConnect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceSAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference. About
- SECSEC Form 10-Q filed by Connect Biopharma Holdings Limited10-Q - Connect Biopharma Holdings Ltd (0001835268) (Filer)
CNTB FAQ
7 questionsWhat does Connect Biopharma Holdings Limited do?
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell...Where does CNTB stock trade?
Connect Biopharma Holdings Limited (CNTB) is listed on NASDAQ.What sector and industry is CNTB in?
Connect Biopharma Holdings Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Connect Biopharma Holdings Limited go public?
Connect Biopharma Holdings Limited (CNTB) completed its IPO in 2021.What are analysts saying about CNTB?
Connect Biopharma Holdings Limited has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $400.00 price target on 2026-10-12. Recent price targets range from $400.00 to $1000.00.What companies are similar to CNTB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CNTB side-by-side with any of them on Quantisnow.How can I track CNTB on Quantisnow?
Quantisnow aggregates Connect Biopharma Holdings Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CNTB to receive live email and push alerts on every new disclosure.